Next Article in Journal
Inflammatory Indexes as Predictive Biomarkers of Postoperative Complications in Oncological Thoracic Surgery
Next Article in Special Issue
Cancer Premature Mortality Costs in Europe in 2020: A Comparison of the Human Capital Approach and the Friction Cost Approach
Previous Article in Journal
Osseous Union after Mandible Reconstruction with Fibula Free Flap Using Manually Bent Plates vs. Patient-Specific Implants: A Retrospective Analysis of 89 Patients
Previous Article in Special Issue
The Economic Burden of Cancer in Canada from a Societal Perspective
Systematic Review

The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context

1
Centre for Outcomes Research and Evaluation, Research Institute of McGill University Health Centre, Montreal, QC H4A 3J1, Canada
2
Experimental Surgery, McGill University, Montreal, QC H3A 0G4, Canada
3
Division of Urology, Department of Surgery, McGill University, Montreal, QC H3A 0G4, Canada
4
Département de Médecine Sociale et Préventive, Université Laval, Quebec City, QC G1V 0A6, Canada
5
Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC G1V 4G2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3393-3424; https://doi.org/10.3390/curroncol29050275
Received: 14 March 2022 / Revised: 27 April 2022 / Accepted: 29 April 2022 / Published: 7 May 2022
Background: Health economic evaluations are needed to assess the impact on the healthcare system of emerging treatment patterns for advanced prostate cancer. The objective of this study is to review the scientific literature identifying cost-effectiveness and cost analyses that are assessing treatments for metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC). Methods: On 29 June 2021, we searched the scientific (MEDLINE, Embase, and EBSCO) and grey literature for health economic studies targeting mHSPC and nmCRPC. We used the CHEC-extended checklist and the Welte checklist for risk-of-bias assessment and transferability analysis, respectively. Results: We retained 20 cost-effectiveness and 4 cost analyses in the mHSPC setting, and 14 cost-effectiveness and 6 cost analyses in the nmCRPC setting. Docetaxel in combination with androgen deprivation therapy (ADT) was the most cost-effective treatment in the mHSPC setting. Apalutamide, darolutamide, and enzalutamide presented similar results vs. ADT alone and were identified as cost-effective treatments for nmCRPC. An increase in costs as patients transitioned from nmCRPC to mCRPC was noted. Conclusions: We concluded that there is an important unmet need for health economic evaluations in the mHSPC and nmCRPC setting incorporating real-world data to support healthcare decision making. View Full-Text
Keywords: prostate cancer; mHSPC; NM-CRPC; review; cost analysis; cost effectiveness; clinical trials; real-world data; healthcare-system perspective; societal perspective prostate cancer; mHSPC; NM-CRPC; review; cost analysis; cost effectiveness; clinical trials; real-world data; healthcare-system perspective; societal perspective
Show Figures

Figure 1

MDPI and ACS Style

Yanev, I.; Gatete, J., Jr.; Aprikian, A.G.; Guertin, J.R.; Dragomir, A. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context. Curr. Oncol. 2022, 29, 3393-3424. https://doi.org/10.3390/curroncol29050275

AMA Style

Yanev I, Gatete J Jr., Aprikian AG, Guertin JR, Dragomir A. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context. Current Oncology. 2022; 29(5):3393-3424. https://doi.org/10.3390/curroncol29050275

Chicago/Turabian Style

Yanev, Ivan, Jessy Gatete Jr., Armen G. Aprikian, Jason R. Guertin, and Alice Dragomir. 2022. "The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context" Current Oncology 29, no. 5: 3393-3424. https://doi.org/10.3390/curroncol29050275

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop